

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: **Q83588**

Shogo ISHIUCHI

Appln. No.: **National Stage Entry of PCT/JP03/03867**

Confirmation No.: Not yet assigned

Group Art Unit: Not yet assigned

Filed: **September 27, 2004**

Examiner: Not yet assigned

For: **THERAPEUTIC AGENT FOR GLIOBLASTOMA**

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents listed on the attached Form PTO/SB/08 A & B (modified), which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents, other than any U.S. patents and patent publications, is submitted herewith.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

INFORMATION DISCLOSURE STATEMENT
National Stage Entry of PCT/JP03/03867:


In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents, together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office.

In addition, WO 00/24395 is cited and discussed on page 6 of the above referenced application, as well as articles from the Proceedings of the National Academy of Sciences of United States of America and Nature Medicine. Also U.S. Patent No. 6,096,743 corresponds to WO 96/10023 and U.S. Patent No. 6,133,258 corresponds to WO 97/17970.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,


for Mark Boland
Registration No. 32,197

REG No.
47,125

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

MB/lck

Date: September 27, 2004

Substitute for Form 1449 A & B/PTO <u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u> <i>(use as many sheets as necessary)</i>				10/509379 <i>Complete if known</i>	
				Application Number	National Stage Entry of PCT/JP03/03867
				Confirmation Number	Not yet assigned
				Filing Date	September 27, 2004
				First Named Inventor	Shogo ISHIUCHI
				Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet 1 of 1				Attorney Docket Number	Q83588

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		6,133,258	A	10-17-2000	Jun-ichi SHISHIKURA, et al.
		6,096,743	A	08-01-2000	Jun-ichi SHISHIKURA, et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		WO	2004/014433	A1	0219-2004	Japan Science and Technology Agency	Abstract
		WO	00/24395	A1	05-04-2000	Hrissanthi Ikonomidou	
		WO	03/000928	A2	01-03-2003	Odin Medical A/S	
		WO	97/17970	A1	05-22-1997	Yamanouchi Pharmaceutical Co., Ltd.	Abstract
		WO	96/10023	A1	04-04-1996	Yamanouchi Pharmaceutical Co., Ltd.	Abstract
		WO	00/54772	A1	09-21-2000	Aventis Pharma S.A.	Abstract

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Mark NOBLE, "Can neural stem cells be used as therapeutic vehicles in the treatment of brain tumors?", NATURE MEDICINE, Vol. 6, No. 4, pgs. 369-370 (April 2000)	
		Wojciech RZESKI, et al., "Glutamate antagonists limit tumor growth", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF UNITED STATES OF AMERICA, Vol. 98, No. 11, pgs. 6372-6377 (May 22, 2001)	
		Shogo ISHIUCHI, et al., "Blockage of Ca ²⁺ -permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells", NATURE MEDICINE, Vol. 8, No. 9, pgs. 971-978, (September 2002)	
		Catarina L. FLORIAN, et al., "Characteristics Metabolic Profiles Revealed by ¹ H NMR Spectroscopy for Three Types of Human Brain and Nervous Systems Tumours", NMR IN BIOMEDICINE, Vol. 8, Pgs. 253-264, (1996)	
		Takahiro TAKANO, et al., "Glutamate release promotes growth of malignant gliomas", NATURE MEDICINE, Vol. 7, No. 9, pgs. 1010-1015 (2001)	
		International Search Report, JPO, June 17, 2003	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.